Exact Sciences Marketing Mix
Go Beyond the Snapshot—Get the Full Strategy
Discover how Exact Sciences aligns product innovation, pricing, distribution and promotion to lead in molecular diagnostics—this preview only scratches the surface. Purchase the full 4P's Marketing Mix Analysis for an editable, data-driven report with actionable insights, slides and benchmarking ready for business or academic use.
Product
Noninvasive CRC screening (Cologuard)
Flagship stool-DNA test for detecting colorectal cancer and advanced adenomas in average-risk adults aged 45–84 per USPSTF guidance. It combines DNA biomarkers and hemoglobin with pivotal sensitivity 92.3% for CRC and specificity 86.6%, outperforming FIT sensitivity in trials. Home collection with prepaid return boosts adherence, and ongoing workflow, UI and reporting iterations aim to reduce false positives and improve user experience.
Precision oncology assays (Oncotype DX)
Oncotype DX are genomic assays that inform prognosis and therapy selection in early-stage breast cancer and have prostate and colon applications, delivering recurrence scores that guide chemotherapy and hormone-therapy decisions to reduce overtreatment. Clinically validated with inclusion in NCCN and ASCO guidelines, the assays bolster oncologist confidence. Integrated, patient-facing reports support shared decision-making between clinicians and patients.
Broader oncology diagnostics portfolio
Exact Sciences' broader oncology diagnostics portfolio complements Cologuard (92.1% sensitivity, 86.6% specificity) with MRD, tumor profiling and advanced diagnostics covering the care continuum. The company emphasizes actionable reports to guide therapy selection and is investing in higher sensitivity/specificity and faster turnaround. Its pipeline includes multi-cancer and next-gen screening programs and builds on the 2019 Genomic Health acquisition for scale.
Patient-centric design and services
Exact Sciences designs a patient-centric end-to-end experience—clear instructions, multilingual support and automated reminders—to reduce friction; telephonic and digital assistance lift correct kit completion and educational materials demystify genomics (Cologuard clinical sensitivity for colorectal cancer 92% and specificity 87%, NEJM 2014), while accessibility features and caregiver support raise completion across populations.
- Kit return improvement: reminder programs can increase returns up to 20%
- Clinical sensitivity: colorectal cancer 92%
- Specificity: 87%
- Multilingual and caregiver outreach boost equity in completion
Clinician-first reporting and integration
Clinician-first reports are standardized, concise, and integrated with major EHRs (Epic, Cerner) to streamline workflows; decision aids and USPSTF/ACS guideline references are embedded to speed interpretation. Dedicated medical affairs and case consultation teams support complex cases, while ongoing provider feedback loops (active in 2024) drive iterative product refinements.
- EHR integration: Epic, Cerner
- Guideline-linked: USPSTF, ACS
- Dedicated medical affairs support
- Continuous provider feedback (2024)
Stool-DNA: 92.3%/86.6% CRC, 20% return
Cologuard flagship stool-DNA screening for average-risk adults (USPSTF-aligned), clinical sensitivity ~92.3% for CRC and specificity ~86.6%, home kit with prepaid return and reminders raising adherence; oncology portfolio (Oncotype DX, MRD, profiling) supports guideline-driven care and integrated EHR reporting. Continuous 2024 provider feedback informs product iteration.
| Metric | Value |
|---|---|
| CRC sensitivity | 92.3% |
| Specificity | 86.6% |
| Kit return uplift | up to 20% |
What is included in the product
Detailed Word Document
Delivers a professionally written, company-specific deep dive into Exact Sciences' Product, Price, Place, and Promotion strategies. Ideal for managers, consultants, and marketers needing a grounded, example-driven breakdown of Exact Sciences' market positioning, competitive context, and strategic implications—ready to repurpose for reports or presentations.
Customizable Excel Spreadsheet
Condenses Exact Sciences’ 4Ps into a high-level, at-a-glance view that relieves analysis overload for leadership and cross‑functional teams; easily customizable for presentations, competitive comparisons, or rapid marketing planning to align strategy and accelerate decision-making.
Place
Provider-driven distribution
Cologuard and Exact Sciences precision tests are ordered by physicians, advanced practitioners and health systems as part of standard care pathways, with dedicated sales and medical teams targeting oncology, primary care and GI channels. Embedded ordering within EHRs and patient portals reduces friction at the point of care and increases adherence to screening workflows. Hospital laboratories and specialty clinics serve as primary access nodes for specimen collection and logistics.
At-home kit logistics
Cologuard kits are shipped directly to patients with prepaid returns to Exact Sciences centralized labs in Madison, WI, supporting a program used by over 6 million patients since launch. Automated reminders and end-to-end tracking improve collection rates and reduce lost samples. Robust stabilization chemistry and controlled shipping protect biomarker integrity. Scalable fulfillment handles national screening campaigns and seasonal spikes of hundreds of thousands of kits.
Central and partner laboratory networks
Testing is performed in CLIA-certified, CAP-accredited central labs to ensure quality and consistency; capacity planning balances turnaround time with peak volumes while maintaining compliance. Select partnerships extend reach into international markets and specialized assays, and integrated data connectivity delivers rapid electronic reports back to providers.
Payer and health system integration
Exact Sciences secures in-network agreements with major commercial plans, Medicare (coverage since 2014), and Medicaid to broaden Cologuard access; payer care-gap programs and ACO partnerships embed screening into population-health workflows. Health system contracts standardize ordering, pricing, and performance metrics, while coverage policies place testing within preventive care benefits.
- Medicare coverage: MolDx decision 2014
- ACO/care-gap integration: embeds screening into workflows
- Contracts: standardize orders, pricing, metrics
- Coverage policies: drive preventive-care placement
Digital channels and patient portals
Population screening: 6,000,000+ tested, mailed kits ~65% completion
Place: Cologuard distributes via physician orders, EHR-embedded workflows and direct-to-patient mailed kits (over 6 million patients tested since launch), with centralized CLIA/CAP labs in Madison, WI and national fulfillment handling seasonal spikes. Mailed kit completion ~65%; Medicare coverage since MolDx decision 2014; payer and ACO contracts embed screening in population-health pathways.
| Metric | Value |
|---|---|
| Patients tested | >6,000,000 |
| Kit completion | ~65% |
| Lab | CLIA/CAP Madison, WI |
| Medicare | Coverage since 2014 |
What You Preview Is What You Download
Exact Sciences 4P's Marketing Mix Analysis
The Exact Sciences 4P's Marketing Mix Analysis shown here is the exact, fully finished document you’ll receive immediately after purchase—no samples or mockups. It’s a complete, editable marketing mix ready for use in strategy, presentations, or reporting. Buy with confidence knowing the preview equals the final deliverable.
Go Beyond the Snapshot—Get the Full Strategy
Discover how Exact Sciences aligns product innovation, pricing, distribution and promotion to lead in molecular diagnostics—this preview only scratches the surface. Purchase the full 4P's Marketing Mix Analysis for an editable, data-driven report with actionable insights, slides and benchmarking ready for business or academic use.
Product
Noninvasive CRC screening (Cologuard)
Flagship stool-DNA test for detecting colorectal cancer and advanced adenomas in average-risk adults aged 45–84 per USPSTF guidance. It combines DNA biomarkers and hemoglobin with pivotal sensitivity 92.3% for CRC and specificity 86.6%, outperforming FIT sensitivity in trials. Home collection with prepaid return boosts adherence, and ongoing workflow, UI and reporting iterations aim to reduce false positives and improve user experience.
Precision oncology assays (Oncotype DX)
Oncotype DX are genomic assays that inform prognosis and therapy selection in early-stage breast cancer and have prostate and colon applications, delivering recurrence scores that guide chemotherapy and hormone-therapy decisions to reduce overtreatment. Clinically validated with inclusion in NCCN and ASCO guidelines, the assays bolster oncologist confidence. Integrated, patient-facing reports support shared decision-making between clinicians and patients.
Broader oncology diagnostics portfolio
Exact Sciences' broader oncology diagnostics portfolio complements Cologuard (92.1% sensitivity, 86.6% specificity) with MRD, tumor profiling and advanced diagnostics covering the care continuum. The company emphasizes actionable reports to guide therapy selection and is investing in higher sensitivity/specificity and faster turnaround. Its pipeline includes multi-cancer and next-gen screening programs and builds on the 2019 Genomic Health acquisition for scale.
Patient-centric design and services
Exact Sciences designs a patient-centric end-to-end experience—clear instructions, multilingual support and automated reminders—to reduce friction; telephonic and digital assistance lift correct kit completion and educational materials demystify genomics (Cologuard clinical sensitivity for colorectal cancer 92% and specificity 87%, NEJM 2014), while accessibility features and caregiver support raise completion across populations.
- Kit return improvement: reminder programs can increase returns up to 20%
- Clinical sensitivity: colorectal cancer 92%
- Specificity: 87%
- Multilingual and caregiver outreach boost equity in completion
Clinician-first reporting and integration
Clinician-first reports are standardized, concise, and integrated with major EHRs (Epic, Cerner) to streamline workflows; decision aids and USPSTF/ACS guideline references are embedded to speed interpretation. Dedicated medical affairs and case consultation teams support complex cases, while ongoing provider feedback loops (active in 2024) drive iterative product refinements.
- EHR integration: Epic, Cerner
- Guideline-linked: USPSTF, ACS
- Dedicated medical affairs support
- Continuous provider feedback (2024)
Stool-DNA: 92.3%/86.6% CRC, 20% return
Cologuard flagship stool-DNA screening for average-risk adults (USPSTF-aligned), clinical sensitivity ~92.3% for CRC and specificity ~86.6%, home kit with prepaid return and reminders raising adherence; oncology portfolio (Oncotype DX, MRD, profiling) supports guideline-driven care and integrated EHR reporting. Continuous 2024 provider feedback informs product iteration.
| Metric | Value |
|---|---|
| CRC sensitivity | 92.3% |
| Specificity | 86.6% |
| Kit return uplift | up to 20% |
What is included in the product
Detailed Word Document
Delivers a professionally written, company-specific deep dive into Exact Sciences' Product, Price, Place, and Promotion strategies. Ideal for managers, consultants, and marketers needing a grounded, example-driven breakdown of Exact Sciences' market positioning, competitive context, and strategic implications—ready to repurpose for reports or presentations.
Customizable Excel Spreadsheet
Condenses Exact Sciences’ 4Ps into a high-level, at-a-glance view that relieves analysis overload for leadership and cross‑functional teams; easily customizable for presentations, competitive comparisons, or rapid marketing planning to align strategy and accelerate decision-making.
Place
Provider-driven distribution
Cologuard and Exact Sciences precision tests are ordered by physicians, advanced practitioners and health systems as part of standard care pathways, with dedicated sales and medical teams targeting oncology, primary care and GI channels. Embedded ordering within EHRs and patient portals reduces friction at the point of care and increases adherence to screening workflows. Hospital laboratories and specialty clinics serve as primary access nodes for specimen collection and logistics.
At-home kit logistics
Cologuard kits are shipped directly to patients with prepaid returns to Exact Sciences centralized labs in Madison, WI, supporting a program used by over 6 million patients since launch. Automated reminders and end-to-end tracking improve collection rates and reduce lost samples. Robust stabilization chemistry and controlled shipping protect biomarker integrity. Scalable fulfillment handles national screening campaigns and seasonal spikes of hundreds of thousands of kits.
Central and partner laboratory networks
Testing is performed in CLIA-certified, CAP-accredited central labs to ensure quality and consistency; capacity planning balances turnaround time with peak volumes while maintaining compliance. Select partnerships extend reach into international markets and specialized assays, and integrated data connectivity delivers rapid electronic reports back to providers.
Payer and health system integration
Exact Sciences secures in-network agreements with major commercial plans, Medicare (coverage since 2014), and Medicaid to broaden Cologuard access; payer care-gap programs and ACO partnerships embed screening into population-health workflows. Health system contracts standardize ordering, pricing, and performance metrics, while coverage policies place testing within preventive care benefits.
- Medicare coverage: MolDx decision 2014
- ACO/care-gap integration: embeds screening into workflows
- Contracts: standardize orders, pricing, metrics
- Coverage policies: drive preventive-care placement
Digital channels and patient portals
Population screening: 6,000,000+ tested, mailed kits ~65% completion
Place: Cologuard distributes via physician orders, EHR-embedded workflows and direct-to-patient mailed kits (over 6 million patients tested since launch), with centralized CLIA/CAP labs in Madison, WI and national fulfillment handling seasonal spikes. Mailed kit completion ~65%; Medicare coverage since MolDx decision 2014; payer and ACO contracts embed screening in population-health pathways.
| Metric | Value |
|---|---|
| Patients tested | >6,000,000 |
| Kit completion | ~65% |
| Lab | CLIA/CAP Madison, WI |
| Medicare | Coverage since 2014 |
What You Preview Is What You Download
Exact Sciences 4P's Marketing Mix Analysis
The Exact Sciences 4P's Marketing Mix Analysis shown here is the exact, fully finished document you’ll receive immediately after purchase—no samples or mockups. It’s a complete, editable marketing mix ready for use in strategy, presentations, or reporting. Buy with confidence knowing the preview equals the final deliverable.
Description
Go Beyond the Snapshot—Get the Full Strategy
Discover how Exact Sciences aligns product innovation, pricing, distribution and promotion to lead in molecular diagnostics—this preview only scratches the surface. Purchase the full 4P's Marketing Mix Analysis for an editable, data-driven report with actionable insights, slides and benchmarking ready for business or academic use.
Product
Noninvasive CRC screening (Cologuard)
Flagship stool-DNA test for detecting colorectal cancer and advanced adenomas in average-risk adults aged 45–84 per USPSTF guidance. It combines DNA biomarkers and hemoglobin with pivotal sensitivity 92.3% for CRC and specificity 86.6%, outperforming FIT sensitivity in trials. Home collection with prepaid return boosts adherence, and ongoing workflow, UI and reporting iterations aim to reduce false positives and improve user experience.
Precision oncology assays (Oncotype DX)
Oncotype DX are genomic assays that inform prognosis and therapy selection in early-stage breast cancer and have prostate and colon applications, delivering recurrence scores that guide chemotherapy and hormone-therapy decisions to reduce overtreatment. Clinically validated with inclusion in NCCN and ASCO guidelines, the assays bolster oncologist confidence. Integrated, patient-facing reports support shared decision-making between clinicians and patients.
Broader oncology diagnostics portfolio
Exact Sciences' broader oncology diagnostics portfolio complements Cologuard (92.1% sensitivity, 86.6% specificity) with MRD, tumor profiling and advanced diagnostics covering the care continuum. The company emphasizes actionable reports to guide therapy selection and is investing in higher sensitivity/specificity and faster turnaround. Its pipeline includes multi-cancer and next-gen screening programs and builds on the 2019 Genomic Health acquisition for scale.
Patient-centric design and services
Exact Sciences designs a patient-centric end-to-end experience—clear instructions, multilingual support and automated reminders—to reduce friction; telephonic and digital assistance lift correct kit completion and educational materials demystify genomics (Cologuard clinical sensitivity for colorectal cancer 92% and specificity 87%, NEJM 2014), while accessibility features and caregiver support raise completion across populations.
- Kit return improvement: reminder programs can increase returns up to 20%
- Clinical sensitivity: colorectal cancer 92%
- Specificity: 87%
- Multilingual and caregiver outreach boost equity in completion
Clinician-first reporting and integration
Clinician-first reports are standardized, concise, and integrated with major EHRs (Epic, Cerner) to streamline workflows; decision aids and USPSTF/ACS guideline references are embedded to speed interpretation. Dedicated medical affairs and case consultation teams support complex cases, while ongoing provider feedback loops (active in 2024) drive iterative product refinements.
- EHR integration: Epic, Cerner
- Guideline-linked: USPSTF, ACS
- Dedicated medical affairs support
- Continuous provider feedback (2024)
Stool-DNA: 92.3%/86.6% CRC, 20% return
Cologuard flagship stool-DNA screening for average-risk adults (USPSTF-aligned), clinical sensitivity ~92.3% for CRC and specificity ~86.6%, home kit with prepaid return and reminders raising adherence; oncology portfolio (Oncotype DX, MRD, profiling) supports guideline-driven care and integrated EHR reporting. Continuous 2024 provider feedback informs product iteration.
| Metric | Value |
|---|---|
| CRC sensitivity | 92.3% |
| Specificity | 86.6% |
| Kit return uplift | up to 20% |
What is included in the product
Detailed Word Document
Delivers a professionally written, company-specific deep dive into Exact Sciences' Product, Price, Place, and Promotion strategies. Ideal for managers, consultants, and marketers needing a grounded, example-driven breakdown of Exact Sciences' market positioning, competitive context, and strategic implications—ready to repurpose for reports or presentations.
Customizable Excel Spreadsheet
Condenses Exact Sciences’ 4Ps into a high-level, at-a-glance view that relieves analysis overload for leadership and cross‑functional teams; easily customizable for presentations, competitive comparisons, or rapid marketing planning to align strategy and accelerate decision-making.
Place
Provider-driven distribution
Cologuard and Exact Sciences precision tests are ordered by physicians, advanced practitioners and health systems as part of standard care pathways, with dedicated sales and medical teams targeting oncology, primary care and GI channels. Embedded ordering within EHRs and patient portals reduces friction at the point of care and increases adherence to screening workflows. Hospital laboratories and specialty clinics serve as primary access nodes for specimen collection and logistics.
At-home kit logistics
Cologuard kits are shipped directly to patients with prepaid returns to Exact Sciences centralized labs in Madison, WI, supporting a program used by over 6 million patients since launch. Automated reminders and end-to-end tracking improve collection rates and reduce lost samples. Robust stabilization chemistry and controlled shipping protect biomarker integrity. Scalable fulfillment handles national screening campaigns and seasonal spikes of hundreds of thousands of kits.
Central and partner laboratory networks
Testing is performed in CLIA-certified, CAP-accredited central labs to ensure quality and consistency; capacity planning balances turnaround time with peak volumes while maintaining compliance. Select partnerships extend reach into international markets and specialized assays, and integrated data connectivity delivers rapid electronic reports back to providers.
Payer and health system integration
Exact Sciences secures in-network agreements with major commercial plans, Medicare (coverage since 2014), and Medicaid to broaden Cologuard access; payer care-gap programs and ACO partnerships embed screening into population-health workflows. Health system contracts standardize ordering, pricing, and performance metrics, while coverage policies place testing within preventive care benefits.
- Medicare coverage: MolDx decision 2014
- ACO/care-gap integration: embeds screening into workflows
- Contracts: standardize orders, pricing, metrics
- Coverage policies: drive preventive-care placement
Digital channels and patient portals
Population screening: 6,000,000+ tested, mailed kits ~65% completion
Place: Cologuard distributes via physician orders, EHR-embedded workflows and direct-to-patient mailed kits (over 6 million patients tested since launch), with centralized CLIA/CAP labs in Madison, WI and national fulfillment handling seasonal spikes. Mailed kit completion ~65%; Medicare coverage since MolDx decision 2014; payer and ACO contracts embed screening in population-health pathways.
| Metric | Value |
|---|---|
| Patients tested | >6,000,000 |
| Kit completion | ~65% |
| Lab | CLIA/CAP Madison, WI |
| Medicare | Coverage since 2014 |
What You Preview Is What You Download
Exact Sciences 4P's Marketing Mix Analysis
The Exact Sciences 4P's Marketing Mix Analysis shown here is the exact, fully finished document you’ll receive immediately after purchase—no samples or mockups. It’s a complete, editable marketing mix ready for use in strategy, presentations, or reporting. Buy with confidence knowing the preview equals the final deliverable.
